The pharmaceutical technology sector continues to attract substantial investment as AI-powered drug discovery, clinical-stage biotechnology, rare-disease therapies, and advanced drug-delivery technologies move further into development and commercialization. The 2025 Financial Times growth ranking included pharma and biotech companies with multi-year growth rates reaching 3,984.8%, illustrating how quickly selected companies in the sector had expanded.
That momentum is continuing in 2026. According to BioPharma Dive, at least 68 venture-backed biotech companies raised more than $9.1 billion between January and June 2026, the highest first-half total since the beginning of 2022 among companies backed by the 26 venture firms it tracks. At the same time, clinical milestones, pharmaceutical partnerships, acquisitions, and commercial launches are providing additional evidence of growth beyond funding alone.
Key Takeaways
- AI drug discovery continues attracting major capital - Isomorphic Labs raised $2.1 billion in 2026 while Insilico, Recursion, and Generate advanced clinical programs
- Clinical progress matters alongside financing - Late-stage trials and FDA approvals provide stronger evidence of development progress than funding alone
- Commercial-stage companies remain important growth stories - BioCryst and UroGen are generating meaningful product revenue
- Acquisitions provide another growth outcome - Johnson & Johnson acquired Intra-Cellular Therapies, while Immedica acquired Marinus Pharmaceuticals in 2025
- Large pharma partnerships validate new platforms - Collaborations with companies such as Lilly, Novartis, Roche, Genentech, and Johnson & Johnson provide additional evidence of industry adoption
Why Pharma Tech Companies Matter
Pharma tech companies combine pharmaceutical development with technologies such as artificial intelligence, computational biology, automation, advanced therapeutic design, and drug-delivery systems. These approaches aim to improve decisions across a development process that remains lengthy, expensive, and exposed to substantial clinical risk.
The financing environment has also become more selective. HSBC reported that healthcare venture momentum strengthened in the first half of 2026, while mega rounds remained a key driver of biopharma funding and AI became increasingly embedded across healthcare sectors.
These companies matter for several reasons:
- Drug discovery efficiency - Computational tools can help prioritize targets and therapeutic candidates earlier
- Clinical development - Technology can support trial design, patient selection, and development decisions
- Precision medicine - Biological and computational data can help companies target narrower patient populations
- New treatment approaches - Pharma tech includes novel formulations, therapeutic modalities, and delivery systems alongside AI platforms
For healthcare and biotech GTM teams, these milestones can help identify companies entering new stages of investment, clinical development, commercialization, or strategic expansion.
1. Evofem Biosciences
Growth Rate: 3,984.8% in the 2025 FT ranking | CEO: Saundra Pelletier | Location: San Diego, California
What They Do
Evofem Biosciences develops women's sexual and reproductive health products. Its portfolio includes PHEXXI, a hormone-free contraceptive vaginal gel, and SOLOSEC, a single-dose treatment for certain sexual-health infections.
Why They're Growing
- Reported record 2025 net sales of $20.2 million, its fifth consecutive year of net-sales growth
- Reduced 2025 operating expenses by 38% and reported $3.4 million in operating income
- Continued pursuing international commercialization agreements and manufacturing-cost reductions
Growth has not been uniform: second-quarter 2026 net sales were $2.6 million versus $4.8 million a year earlier. The current picture is therefore more mixed than the historical FT growth rate alone suggests.
Industry Importance
Evofem addresses women's health markets with non-hormonal contraception and sexual-health treatments, areas where product choice remains an important part of patient care.
2. Intra-Cellular Therapies
Growth Rate: 1,951.3% in the 2025 FT ranking | Current Status: Acquired by Johnson & Johnson
What They Do
Intra-Cellular Therapies developed treatments for central nervous system disorders, led by CAPLYTA (lumateperone) for schizophrenia and bipolar depression.
Why They're Growing
The company's growth ultimately led to a major strategic exit. Johnson & Johnson completed its approximately $14.6 billion acquisition of Intra-Cellular Therapies in April 2025, after which the company became part of Johnson & Johnson Innovative Medicine.
CAPLYTA received FDA approval as an adjunctive treatment for major depressive disorder in November 2025, and additional long-term schizophrenia data were added to its U.S. label in April 2026.
Industry Importance
Intra-Cellular illustrates how commercial traction and a differentiated CNS portfolio can culminate in a large pharmaceutical acquisition rather than continued growth as an independent company.
3. Isomorphic Labs
Recent Funding: $2.1B Series B, May 2026 | Founded: 2021
What They Do
Isomorphic Labs applies frontier AI to drug design and development. The company builds on technologies associated with Google DeepMind and AlphaFold while developing its broader Isomorphic Labs Drug Design Engine.
Why They're Growing
- Raised $2.1 billion in Series B funding led by Thrive Capital in May 2026
- Continues pharmaceutical collaborations with Novartis and Eli Lilly
- Added a research collaboration with Johnson & Johnson in January 2026
- Is using new capital to expand its internal therapeutic pipeline and global operations
The 2026 financing follows the company's $600 million external funding round in 2025 and represents a significant increase in capital available for AI-enabled drug development.
Industry Importance
Isomorphic is testing whether advances in structural biology and predictive AI can translate into repeatable drug-design programs rather than remaining primarily research tools.
4. Insilico Medicine
Recent Funding: $110M Series E, 2025 | Status: Public, HKEX: 3696
What They Do
Insilico Medicine operates the Pharma.AI platform, which applies generative AI to target discovery, molecular design, and clinical-development planning.
Why They're Growing
- Initiated a Phase III trial for Rentosertib in July 2026
- Expected first-half 2026 revenue of approximately $102.5 million to $106.5 million, representing roughly 273% to 287% year-over-year growth
- Continues expanding pharmaceutical collaborations and its internal clinical pipeline
Rentosertib represents one of the most advanced examples of a drug whose target and molecular structure were developed with substantial AI support.
Industry Importance
Insilico provides clinical-stage evidence that generative AI can contribute to drug programs beyond early target or molecule discovery.
5. Recursion Pharmaceuticals
Status: Public, NASDAQ: RXRX | CEO: Najat Khan
What They Do
Recursion operates the Recursion OS, an AI-native drug-discovery and development platform combining large-scale biological experiments, machine learning, chemistry, and clinical data.
Why They're Growing
- Reports five clinical-stage programs
- Has generated more than $500 million in realized inflows from pharmaceutical partnerships
- Genentech advanced the first neuroscience target from its collaboration with Recursion into a joint early-discovery program in August 2026
- REC-7735 received IND clearance for a planned Phase I/II trial
Industry Importance
Recursion's progress provides a test of whether large biological datasets and AI models can consistently generate useful targets, drug candidates, and clinical programs.
6. Generate Biomedicines
CEO: Michael Nally | Status: Public, NASDAQ: GENB
What They Do
Generate Biomedicines combines machine learning with large-scale experimentation to design protein therapeutics with predefined biological properties.
Why They're Growing
- Completed its IPO in February 2026, pricing 25 million shares at $16 each for expected gross proceeds of $400 million
- Has multiple clinical-stage programs
- Its GB-0895 program is being evaluated in two global Phase III studies for severe asthma
Industry Importance
Generate represents the generative-biology approach to pharma tech, using computational design to create purpose-built therapeutic proteins rather than relying solely on naturally occurring molecules.
7. Verdiva Bio
Series A Funding: More than $410M, January 2025
What They Do
Verdiva Bio develops obesity and cardiometabolic medicines, including oral and injectable candidates designed to improve treatment convenience and durability.
Why They're Growing
- Launched with more than $410 million in Series A financing
- Completed enrollment in its Phase IIb EVOLVE-2 study in February 2026
- Enrolled more than 200 participants across 22 U.S. sites
- Expects EVOLVE-2 topline results by the end of 2026
Industry Importance
Verdiva combines a large early-stage financing round with exposure to the rapidly expanding obesity-treatment market. Its lead program targets a potential once-weekly oral GLP-1 treatment.
8. Marinus Pharmaceuticals
Growth Rate: 1,703.8% in the 2025 FT ranking | Current Status: Acquired by Immedica
What They Do
Marinus Pharmaceuticals developed ZTALMY (ganaxolone), a treatment for seizures associated with CDKL5 deficiency disorder.
Why They're Growing
Marinus' independent growth story ended when Immedica completed its acquisition of the company in February 2025. ZTALMY became part of Immedica's rare-disease portfolio, and Immedica subsequently became the product's marketing authorization holder in the European Union.
Industry Importance
Marinus demonstrates how innovation in ultra-rare neurological diseases can create strategic value for larger rare-disease companies. Its acquisition is now a more relevant growth outcome than treating Marinus as an independent 2026 startup.
9. BioCryst Pharmaceuticals
Growth Rate: 1,760.6% in the 2025 FT ranking | CEO: Charlie Gayer
What They Do
BioCryst develops treatments for rare diseases, led by ORLADEYO, an oral once-daily therapy for hereditary angioedema.
Why They're Growing
- Reported $218.3 million in Q2 2026 total revenue
- Generated $158.2 million in quarterly ORLADEYO revenue
- Maintained 2026 ORLADEYO revenue guidance of $625 million to $645 million
- Expanded its rare-disease pipeline with navenibart following its acquisition of Astria Therapeutics
Industry Importance
BioCryst demonstrates how differentiated formulations can create meaningful commercial growth in rare diseases while providing capital to expand into additional therapeutic programs.
10. UroGen Pharma
Growth Rate: 601% in the 2025 FT ranking | CEO: Liz Barrett
What They Do
UroGen Pharma develops localized treatments for urothelial cancers using its proprietary sustained-release RTGel drug-delivery technology.
Why They're Growing
- Received FDA approval for ZUSDURI in June 2025
- Generated $50.4 million in ZUSDURI revenue in Q2 2026, up 73% quarter over quarter
- Reported $72.5 million in total Q2 revenue versus $24.2 million a year earlier
- Plans an NDA submission for next-generation UGN-103 in Q3 2026
Industry Importance
UroGen demonstrates how drug-delivery technology can create new treatment options around established therapeutic agents. Its 2026 revenue provides current commercial evidence beyond its earlier growth ranking.
How Landbase Helps GTM Teams Target Growing Pharma Tech Companies
For RevOps teams, GTM engineers, and sales organizations targeting pharmaceutical technology, the challenge is identifying companies at the right stage of development. A startup raising a Series A, a clinical-stage biotech entering Phase III, and a commercial pharmaceutical company launching an FDA-approved product can all create different GTM opportunities.
Landbase CLI provides programmatic access to Landbase data and agent workflows from the terminal and environments such as Claude Code and Codex.
Why Landbase Works for Pharma Tech Targeting
- Natural-language audience search - Teams can describe criteria such as clinical stage, geography, funding, employee size, or technology focus
- Growth-signal analysis - Buying signals can combine funding, hiring, executive changes, and other company events
- Company and contact enrichment - Existing pharma lists can be processed through matching and enrichment
- Batch workflows - File-based workflows can support larger account lists
- Agent-ready outputs - Structured datasets can move into scripts, analysis environments, CRM workflows, Claude Code, or Codex
For teams mapping biotech and life-sciences markets, these workflows can help maintain account intelligence as companies raise funding, advance clinical programs, complete acquisitions, or launch products.
Frequently Asked Questions
What defines a "pharma tech" company, and how does it differ from traditional pharmaceutical companies?
Pharma tech companies make technologies such as artificial intelligence, machine learning, computational biology, automation, or advanced drug-delivery systems central to pharmaceutical development. Some operate primarily as technology platforms, while others use their technology to build proprietary therapeutic pipelines. The distinction is becoming less rigid as traditional pharmaceutical companies increasingly adopt many of the same technologies.
How do funding rounds like Series A or Series B impact a pharma tech company's growth trajectory?
Funding provides capital for platform development, hiring, preclinical research, clinical trials, manufacturing, and commercialization preparation. Large rounds can allow companies to advance multiple programs simultaneously, but financing alone does not demonstrate clinical success or buying readiness. Funding becomes more informative when combined with pipeline progress, partnerships, regulatory milestones, or organizational expansion.
What kind of job opportunities are available in the pharma tech sector?
Pharma tech companies hire across scientific, technical, clinical, regulatory, and commercial functions. Common roles include computational biologists, machine-learning engineers, data scientists, clinical-operations specialists, regulatory professionals, business-development leaders, and commercial teams. Hiring patterns can also provide useful evidence that a company is expanding a particular function or moving into a new development stage.
How do AI and machine learning contribute to pharma tech company growth?
AI and machine learning can support target identification, molecule and protein design, biological-data analysis, clinical-development planning, and research automation. Companies such as Isomorphic Labs, Insilico Medicine, Recursion, and Generate Biomedicines apply these technologies at different stages of pharmaceutical R&D. Clinical validation remains essential because improved computational predictions do not automatically translate into approved medicines.
What are common challenges faced by fast-growing pharma tech startups?
Pharma tech companies face clinical failure risk, regulatory uncertainty, long development timelines, capital requirements, and intense competition for specialized talent. They may also need to balance proprietary drug development with partnerships while protecting intellectual property and maintaining sufficient cash runway. GTM teams can use structured account research alongside company, funding, and growth signals to follow these businesses as their operating priorities change.
.png)
.png)
